Registro de Citas
Cita APA (7a ed.)
Witzig, T. E., Tomblyn, M. B., Misleh, J. G., Kio, E. A., Sharkey, R. M., Wegener, W. A., & Goldenberg, D. M. (2014). Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: A phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Ferrata Storti Foundation.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Witzig, Thomas E., Michael B. Tomblyn, Jamal G. Misleh, Ebenezer A. Kio, Robert M. Sharkey, William A. Wegener, y David M. Goldenberg. Anti-CD22 90Y-epratuzumab Tetraxetan Combined with Anti-CD20 Veltuzumab: A Phase I Study in Patients with Relapsed/refractory, Aggressive Non-Hodgkin Lymphoma. Ferrata Storti Foundation, 2014.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Witzig, Thomas E., et al. Anti-CD22 90Y-epratuzumab Tetraxetan Combined with Anti-CD20 Veltuzumab: A Phase I Study in Patients with Relapsed/refractory, Aggressive Non-Hodgkin Lymphoma. Ferrata Storti Foundation, 2014.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.